Welcome, Introduction, Polling Questions
Overview and Rationale for Testing for NTRK Gene Fusions
- TRK biology and oncogenesis/NTRK fusion frequency and diagnosis across histologies
- Clinical data and current indications for TRK inhibitors
- Future directions
Overview and Rationale for Testing RET Gene Fusions
- RET alterations and oncogenesis/RET fusion frequency and diagnosis across histologies
- Clinical data and current indications for RET inhibitors
- Future directions
Evidence Based Testing Strategies to Detect Appropriate Fusions and Mutations
- Methods of detection of NTRK and RET fusions
Audience Question and Answer Session
Date / Time
Saad A. Khan, MD
Assistant Professor of Medicine (Oncology)
Leader, Endocrine Cancers Research Group
Stanford Cancer Institute
Sandip P. Patel, MD
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California
Jessica Bauman, MD
Department of Hematology-Oncology
Fox Chase Cancer Center
Jonathan Dowell, MD
Associate Professor of Internal Medicine
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Chief, Section of Hematology/Oncology
Dallas VA Medical Center
Nisha Mohindra, MD
Department of Medicine
Conor Ernst Steuer, MD
Department of Medical Oncology
Winship Cancer Institute of Emory University
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung or thyroid cancers.
This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, nurses, pharmacists, and other healthcare professionals who care for patients with lung or thyroid cancer.
Upon completion of this activity, participants should be able to:
- Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
- Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
- Formulate strategies for integrating TRK and RET inhibitors into the management of eligible patients with NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status
- Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy
- Manage treatment-related symptoms associated with the treatment of RET altered or NTRK fusion–positive cancer
- Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-214-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.